✦ LIBER ✦

An in vivo and in vitro trial of aclarubicin in metastatic breast cancer: a novel approach to the study of analogs

✍ Scribed by Ronald B. Natale; Robert L. Cody; Michael S. Simon; Richard H. Wheeler

Publisher: Springer
Year: 1993
Tongue: English
Weight: 428 KB
Volume: 31
Category: Article
ISSN: 0344-5704
DOI: 10.1007/bf00685040

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II study of S-1 in patients with

A phase II study of S-1 in patients with metastatic breast cancer — A Japanese trial by the S-1 cooperative study group, breast cancer working group

✍ Toshiaki Saeki; Shigemitsu Takashima; Muneaki Sano; Noboru Horikoshi; Shigeto Mi 📂 Article 📅 2004 🏛 Springer Japan 🌐 English ⚖ 990 KB

The degradation profile of novel, biores

The degradation profile of novel, bioresorbable PCL–TCP scaffolds: An in vitro and in vivo study

✍ A. Yeo; B. Rai; E. Sju; J.J. Cheong; S.H. Teoh 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 627 KB

## Abstract Degradation studies of scaffolds are important in bone tissue engineering. Previously, novel poly(ε‐caprolactone)–20% tricalcium phosphate (PCL–TCP) based scaffolds were developed and proven useful for bone regeneration. In this study __in vitro__ degradation analyses were carried out w

Efficacy of transfection rates on head a

Efficacy of transfection rates on head and neck squamous cell cancer by a novel adenovirus: An in vivo and in vitro study

✍ Elise S. Lalonde; Gregory Beyer; Paul L. Friedlander; Jay K. Kolls 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 145 KB

## Abstract ## Introduction Internalization of wild‐type adenovirus is dependent on binding to a coxsackie‐adenovirus receptor (CAR). Unfortunately, many tumors lack these receptors. We hypothesized that a novel RGD adenovirus, which binds by way of cellular integrins, would improve the transfecti

Phase 2 trial of a novel capecitabine do

Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer

✍ Devika Gajria; Kim Feigin; Lee K. Tan; Sujata Patil; Stephanie Geneus; Maria The 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB 👁 1 views

Methotrexate, vinblastine, doxorubicin,

Methotrexate, vinblastine, doxorubicin, and cisplatin in metastatic breast cancer. A phase II trial of the hoosier oncology group

✍ Bruce J. Roth; George W. Sledge Jr; Stephen D. Williams; Steven C. Meyer; Rafat 📂 Article 📅 1991 🏛 John Wiley and Sons 🌐 English ⚖ 490 KB 👁 2 views

Forty-six eligible patients with metastatic breast cancer (MBC) were treated with a combination of methotrexate, vinblastine, doxorubicin, and cisplatin (M-VAC) as first-line chemotherapy. Of 44 patients evaluable for response, 28 (64%) had an objective response, including seven (16%) who had a comp

A controlled study in the use of combine

A controlled study in the use of combined drug therapy for metastatic breast cancer

✍ Kurt W. Brunner; Roland W. Sonntag; Georg Martz; Hans Jörg Senn; Paul Obrecht; P 📂 Article 📅 1975 🏛 John Wiley and Sons 🌐 English ⚖ 987 KB